Cargando…

A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HD...

Descripción completa

Detalles Bibliográficos
Autores principales: Farr, Gist H., Morris, Melanie, Gomez, Arianna, Pham, Thao, Kilroy, Elisabeth, Parker, Elizabeth U., Said, Shery, Henry, Clarissa, Maves, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559456/
https://www.ncbi.nlm.nih.gov/pubmed/33059738
http://dx.doi.org/10.1186/s13395-020-00251-4
_version_ 1783594865328652288
author Farr, Gist H.
Morris, Melanie
Gomez, Arianna
Pham, Thao
Kilroy, Elisabeth
Parker, Elizabeth U.
Said, Shery
Henry, Clarissa
Maves, Lisa
author_facet Farr, Gist H.
Morris, Melanie
Gomez, Arianna
Pham, Thao
Kilroy, Elisabeth
Parker, Elizabeth U.
Said, Shery
Henry, Clarissa
Maves, Lisa
author_sort Farr, Gist H.
collection PubMed
description BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HDACi) have been shown to ameliorate DMD phenotypes in mouse and zebrafish animal models. The HDACi givinostat has shown promise for DMD in clinical trials. However, beyond a small group of HDACi, other classes of epigenetic small molecules have not been broadly and systematically studied for their benefits for DMD. METHODS: We used an established animal model for DMD, the zebrafish dmd mutant strain sapje. A commercially available library of epigenetic small molecules was used to treat embryonic-larval stages of dmd mutant zebrafish. We used a quantitative muscle birefringence assay in order to assess and compare the effects of small-molecule treatments on dmd mutant zebrafish skeletal muscle structure. RESULTS: We performed a novel chemical-combination screen of a library of epigenetic compounds using the zebrafish dmd model. We identified candidate pools of epigenetic compounds that improve skeletal muscle structure in dmd mutant zebrafish. We then identified a specific combination of two HDACi compounds, oxamflatin and salermide, that ameliorated dmd mutant zebrafish skeletal muscle degeneration. We validated the effects of oxamflatin and salermide on dmd mutant zebrafish in an independent laboratory. Furthermore, we showed that the combination of oxamflatin and salermide caused increased levels of histone H4 acetylation in zebrafish larvae. CONCLUSIONS: Our results provide novel, effective methods for performing a combination of small-molecule screen in zebrafish. Our results also add to the growing evidence that epigenetic small molecules may be promising candidates for treating DMD.
format Online
Article
Text
id pubmed-7559456
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75594562020-10-15 A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy Farr, Gist H. Morris, Melanie Gomez, Arianna Pham, Thao Kilroy, Elisabeth Parker, Elizabeth U. Said, Shery Henry, Clarissa Maves, Lisa Skelet Muscle Research BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HDACi) have been shown to ameliorate DMD phenotypes in mouse and zebrafish animal models. The HDACi givinostat has shown promise for DMD in clinical trials. However, beyond a small group of HDACi, other classes of epigenetic small molecules have not been broadly and systematically studied for their benefits for DMD. METHODS: We used an established animal model for DMD, the zebrafish dmd mutant strain sapje. A commercially available library of epigenetic small molecules was used to treat embryonic-larval stages of dmd mutant zebrafish. We used a quantitative muscle birefringence assay in order to assess and compare the effects of small-molecule treatments on dmd mutant zebrafish skeletal muscle structure. RESULTS: We performed a novel chemical-combination screen of a library of epigenetic compounds using the zebrafish dmd model. We identified candidate pools of epigenetic compounds that improve skeletal muscle structure in dmd mutant zebrafish. We then identified a specific combination of two HDACi compounds, oxamflatin and salermide, that ameliorated dmd mutant zebrafish skeletal muscle degeneration. We validated the effects of oxamflatin and salermide on dmd mutant zebrafish in an independent laboratory. Furthermore, we showed that the combination of oxamflatin and salermide caused increased levels of histone H4 acetylation in zebrafish larvae. CONCLUSIONS: Our results provide novel, effective methods for performing a combination of small-molecule screen in zebrafish. Our results also add to the growing evidence that epigenetic small molecules may be promising candidates for treating DMD. BioMed Central 2020-10-15 /pmc/articles/PMC7559456/ /pubmed/33059738 http://dx.doi.org/10.1186/s13395-020-00251-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Farr, Gist H.
Morris, Melanie
Gomez, Arianna
Pham, Thao
Kilroy, Elisabeth
Parker, Elizabeth U.
Said, Shery
Henry, Clarissa
Maves, Lisa
A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title_full A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title_fullStr A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title_full_unstemmed A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title_short A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
title_sort novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of duchenne muscular dystrophy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559456/
https://www.ncbi.nlm.nih.gov/pubmed/33059738
http://dx.doi.org/10.1186/s13395-020-00251-4
work_keys_str_mv AT farrgisth anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT morrismelanie anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT gomezarianna anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT phamthao anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT kilroyelisabeth anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT parkerelizabethu anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT saidshery anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT henryclarissa anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT maveslisa anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT farrgisth novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT morrismelanie novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT gomezarianna novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT phamthao novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT kilroyelisabeth novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT parkerelizabethu novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT saidshery novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT henryclarissa novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy
AT maveslisa novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy